Riskpilot← Back to searchSign inGet full accessJAMCO Pharma Consulting AB
ABActiveOrg 5590790837Sockenvägen 464Research and experimental development on natural sciences and engineering · NACE 7210Est. 20161-4 employees
Revenue 2025
SEK 5,2M
-12% vs 2024
EBITDA margin
66.2%
-8% vs 2024
Equity ratio
82.5%
Financial strength
Net profit 2025
SEK 2M
-20% vs 2024
| Revenue | SEK 5,2M | -12% |
| EBITDA | SEK 3,4M | -8% |
| Net profit | SEK 2M | -20% |
| Total assets | SEK 26,5M | +4% |
| Equity | SEK 21,8M | +7% |
| Employees | — | — |
Legal name
JAMCO Pharma Consulting AB
Org number
5590790837
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6 oktober 2016
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva professionell rådgivning till företag inom läkemedelsindustri och bioteknologi avseende klinisk utvecklingsstrategi samt därmed förenlig verksamhet.
Address
Sockenvägen 464
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4 855 | 6 107 | 6 610 | 5 847 | 5 157 |
| Staff expenses | — | — | −1 860 | −1 580 | −994 |
| EBITDA | 3 265 | 1 975 | 4 187 | 3 692 | 3 415 |
| Depreciation & amort. | −0 | −0 | — | −18 | −84 |
| EBIT | 3 265 | 1 975 | 4 187 | 3 674 | 3 331 |
| Net financials | 81 | 1 453 | 402 | 461 | 81 |
| Profit before tax | 2 518 | 3 249 | 7 309 | 3 113 | 2 523 |
| Tax | −533 | −329 | −1 508 | −632 | −550 |
| Net profit | 1 985 | 2 920 | 5 801 | 2 480 | 1 973 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 13 616 | 18 211 | 22 237 | 25 384 | 26 471 |
| Equity | 9 155 | 12 074 | 17 875 | 20 355 | 21 829 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 774 | 1 917 | 2 862 | 2 506 | 1 232 |
| Total debt | 774 | 1 917 | 2 862 | 2 506 | 1 232 |
EBITDA margin
66.2%
This company
15.8%
Market median
+319% vs market
20212025
Equity ratio
82.5%
This company
38.2%
Market median
+116% vs market
20212025
Return on equity
9.0%
This company
18.4%
Market median
-51% vs market
20212025
Net profit margin
38.3%
This company
8.1%
Market median
+373% vs market
20212025
Asset turnover
0.19×
This company
1.12×
Market median
-83% vs market
20212025
Debt / equity
0.21×
This company
0.62×
Market median
+66% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-09-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
OH Audit | Audit | 2022 |
EA Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of JAMCO Pharma Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Olle Henrik Hillbom | Audit | 0 companies |
| Eric Alexander John Mercer | Chief Executive Officer | 0 companies |
| Hanna Maria Katarina Jansson Mercer | Deputy Board Member | 0 companies |